154476-25-2

Basic information

• Product Name: Ketorolac Related Compound B (20 mg) (5-benzoyl-2,3-dihydro-1H-pyrrolizin-1-ol)
• Synonyms: Ketorolac Related Compound B (20 mg) (5-benzoyl-2,3-dihydro-1H-pyrrolizin-1-ol);Ketorolac 1-Hydroxy Analogue;Ketorolac IMpurity A;Descarboxy 1-Hydroxy Ketorolac;Ketorolac Related CoMpound B;Ketorolac EP Impurity A;(7-hydroxy-6,7-dihydro-5H-pyrrolizin-3-yl)-phenylmethanone
• CAS NO: 154476-25-2
• Molecular Formula: C14H13NO2
• Molecular Weight: 227.25852
• Mol File: 154476-25-2.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 437.6±35.0 °C(Predicted)
• Appearance: /
• Density: 1.27±0.1 g/cm3(Predicted)
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 14.73±0.20(Predicted)
• CAS DataBase Reference: Ketorolac Related Compound B (20 mg) (5-benzoyl-2,3-dihydro-1H-pyrrolizin-1-ol)(CAS DataBase Reference)
• NIST Chemistry Reference: Ketorolac Related Compound B (20 mg) (5-benzoyl-2,3-dihydro-1H-pyrrolizin-1-ol)(154476-25-2)
• EPA Substance Registry System: Ketorolac Related Compound B (20 mg) (5-benzoyl-2,3-dihydro-1H-pyrrolizin-1-ol)(154476-25-2)

Safety Data

• Hazardous Substances Data: 154476-25-2(Hazardous Substances Data)

Usage

Description

Ketorolac Related Compound B (20 mg) (5-benzoyl-2,3-dihydro-1H-pyrrolizin-1-ol) is an impurity found in Ketorolac (K235650), which is an analgesic and anti-inflammatory agent. It is a chemical compound derived from the parent drug Ketorolac, and its presence in the drug may affect its efficacy and safety.

Uses

Used in Pharmaceutical Industry:
Ketorolac Related Compound B (20 mg) (5-benzoyl-2,3-dihydro-1H-pyrrolizin-1-ol) is used as an impurity in the manufacturing process of Ketorolac (K235650), an analgesic and anti-inflammatory agent. The presence of this compound in the final product needs to be controlled and monitored to ensure the safety and efficacy of the drug. It is essential to maintain the quality and purity of the active pharmaceutical ingredient (API) to avoid any adverse effects on patients.
In the pharmaceutical industry, the control and management of impurities like Ketorolac Related Compound B are crucial for the development, manufacturing, and quality control of drugs. This ensures that the final drug product meets the required safety and efficacy standards, providing the desired therapeutic benefits to patients while minimizing potential side effects and risks.

Upstream product

• 74103-06-3 Ketorolac 
• 77-86-1 2-amino-2-hydroxymethyl-1,3-propanediol 

Relevant articles and documents

Mechanism of oxidation of ketorolac by hexacyanoferrate(III) in aqueous alkali: A thermodynamics and kinetics study

The kinetics of the oxidation of ketorolac by hexacyanoferrate(III) (HCF) in aqueous alkaline medium at a constant ionic strength of 0.75 mol·dm-3 was studied spectrophotometrically at 300 K. A plausible mechanism was proposed and the rate law was derived. The mechanism of oxidation of ketorolac (KET) in alkaline medium has been shown to proceed via a KET-HCF complex, which decomposes in a slow step followed by other fast steps to give the products. The main oxidative product was identified as (2,3-dihydro-1-hydroxy-1H-pyrrolizin-5-yl-)(phenyl)methanone and is characterized by its LC-ESI-MS spectrum. Thermodynamic parameters of various equilibria of the mechanism were calculated and activation parameters ΔH A, ΔS A, ΔG A and log10 A were found to be 29.9 kJ·mol-1, -220 J·K -1·mol-1, 96 kJ·mol-1 and 2.70 respectively.

Characterization of forced degradation products of ketorolac tromethamine using LC/ESI/Q/TOF/MS/MS and in silico toxicity prediction

Ketorolac, a nonsteroidal anti-inflammatory drug, was subjected to forced degradation studies as per International Conference on Harmonization guidelines. A simple, rapid, precise, and accurate high-performance liquid chromatography combined with electrospray ionization quadrupole time-of-flight tandem mass spectrometry (LC/ESI/Q/TOF/MS/MS) method has been developed for the identification and structural characterization of stressed degradation products of ketorolac. The drug was found to degrade in hydrolytic (acidic, basic, and neutral), photolytic (acidic, basic, and neutral solution), and thermal conditions, whereas the solid form of the drug was found to be stable under photolytic conditions. The method has shown adequate separation of ketorolac tromethamine and its degradation products on a Grace Smart C-18 (250-mm-×-4.6-mm i.d., 5-μm) column using 20-mM ammonium formate (pH-=-3.2): acetonitrile as a mobile phase in gradient elution mode at a flow rate of 1.0-ml/min. A total of nine degradation products were identified and characterized by LC/ESI/MS/MS. The most probable mechanisms for the formation of degradation products have been proposed on the basis of a comparison of the fragmentation of the [M-+-H]+ ions of ketorolac and its degradation products. In silico toxicity of the drug and degradation products was investigated by using topkat and derek softwares. The method was validated in terms of specificity, linearity, accuracy, precision, and robustness as per International Conference on Harmonization guidelines. Copyright